Current status of immunomodulatory therapies in adult sepsis patients: where do we stand?

Key Points

• The aim is to evaluate the current role of immunomodulatory therapies and precision immunotherapy in managing adult sepsis.
• Review of recent studies on immunotherapy in sepsis patients
• Identification and categorization of biomarkers into different endotypes
• Discussion on adaptive clinical trial designs and immune monitoring processes
• Biomarkers effectively classify sepsis patients into distinct endotypes
• Precision immunotherapy shows potential for improving treatment outcomes
• Adaptive strategies may enhance the management of sepsis through personalized approaches

Abstract